JPRN-jRCTs031210565招募中2 期
A multicenter, phase II trial to investigate the safety and efficacy of Panitumumab and Irinotecan in Neo Ras Wild type metastatic colorectal cancer patients - C-PROWESS study
Shinozaki Eiji0 个研究点目标入组 30 人开始时间: 2022年1月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients eligible for inclusion in this study have to meet all of the following criteria:
- •1) Must give written Informed Consent
- •2) Histologically proven diagnosis of colorectal adenocarcinoma
- •3) Advanced or recurrent colorectal cancer (excluding appendix and anal canal cancer)
- •4) Age>= 20 years
- •5) Eastern Cooperative Oncology Group (ECOG) performance status <= 2
- •6) At least one measurable lesion according to RECIST version 1.1 criteria evaluated by CT or MRI within 28 days before registration
- •7) RAS mutation (MT) (KRAS/NRAS exon 2, 3, or 4 MT) confirmed by tumor histology prior to the study enrollment
- •8) Must have had documentation of the RAS WT confirmed within 28 days from test result date by ctDNA analysis using the OncoBEAM (TM) RAS CRC KIT
- •9) Must have confirmed refractory or intolerant to previous treatments with chemotherapies including fluoropyrimidines, oxaliplatin, or irinotecan (irinotecan is applied to refractory only), regardless of prior treatment with trifluridine tipiracil hydrochloride, regorafenib, or angiogenesis inhibitors.
- •10) Life expectancy of at least 60 days
- •11) Adequate organ functions (bone marrow, liver, renal functions) as defined by the following laboratory values obtained within 14 days prior to the study enrollment:
- •a.Absolute neutrophil count >= 1500/ mm3
- •b.Platelets >= 75000/mm3
- •c.Serum total bilirubin <= 1.5 mg/dL
- •d.Serum AST(GOT) and ALT(GPT) <= 100 U/L(except for patients with tumor involvement of the liver who must have AST and ALT <= 200 U/L)
- •e.Serum creatinine <= 1.5 mg/d
排除标准
- •Patients eligible for inclusion in this study must not meet any of the following criteria:
- •1) Evidence of BRAF V600E MT by tumor histology.
- •2) Treated with blood transfusion, blood products, or hematopoietic factor products such as Granulocyte Colony Stimulating Factor within 7 days prior to enrollment in this study.
- •3) Have a history of severe drug hypersensitivity or severe drug allergy
- •4) Active infection (fever of 38 degree or higher due to infection).
- •5) Ascites, pleural effusion, or pericardial effusion requiring continuous drainage.
- •6) Uncontrolled diabetes mellitus.
- •7) Uncontrolled hypertension.
- •8) Patients who have been treated with any of the following treatments prior to starting study drug:
- •a.Extensive surgery <= 4 weeks prior to starting study drug (e.g., surgical treatment with organ resection, excluding colostomy)
- •b.Proctocolectomy <= 2 weeks prior to starting study drug
- •c.Any chemotherapy <= 2 weeks prior to starting study drug
- •d.Radiotherapy <= 2 weeks prior to starting study drug
- •9) Clinically significant electrocardiographic abnormality or clinically significant cardiovascular accidents within 6 months prior to study enrollment, including myocardial infarction, severe unstable angina, or New York Heart Association functional classification class III or IV congestive heart failure.
- •10) Patients with severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema).
- •11) History of clinically significant mental disorder or central nervous system disorder.
- •12) Symptomatic brain metastasis or clinically suspected brain metastasis upon symptoms.
- •13) Diarrhea that interferes with daily life.
- •14) Intestinal paralysis, intestinal obstruction.
- •15) Co-existing active malignancies.
- •16) Pregnant or lactating women; women of childbearing potential or men with women partners of childbearing potential who are unwilling to use a highly effective method of contraception or avoid intercourse during and upon completion of the study. 17) Patients who are judged by the site physician to be inappropriate for this study.
- •18) Patients who have been treated with EGFR inhibitors prior to starting study drug.
研究者
相似试验
进行中（未招募）
1 期
A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients =60 years with AML not eligible for conventionalChemotherapyMedDRA - 10000886, akute myeloische Leukämie, acute myeloid leukemiaC92.0Acute myeloblastic leukaemia [AML]DRKS00000580niversität Leipzig13
进行中（未招募）
不适用
A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients =60 years with AML not eligible for conventionalChemotherapy - ClofarabineAcute myeloid leukaemiaMedDRA version: 12.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaMedDRA version: 12.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaEUCTR2009-017347-33-DEniversity of Leipzig60
已完成
2 期
A phase II, multicenter study to investigate the safety and efficacy of atezolizumab monotherapy as a sequential therapy following chemoradiotherapy in patients with locally advanced unresectable esophageal cancerEsophageal cancerJPRN-UMIN000034373ational Cancer Center Hospital East50
已完成
不适用
Phase II Multicenter Clinical Trial to evaluate the immune response generation capacity and the safety of the ALVAC-HIVVCP1452 Vaccine administered alone and in combination with the MN rpg 120 / HIV-1 vaccine in humans from Brazil, Haiti, Peru and Trinidad and Tobago.-B23 Human immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in other conditionsB23PER-036-01FRED HUTCHINSON CANCER RESEARCH CENTER,
进行中（未招募）
不适用
Clinical trials to demonstrate clinical efficacy with lanalidomide and dexamethasone in patients with multiple myelomaNeoplasmsKCT0003558Kosin University Gospel Hospital70